---

---

 

BioLineRx Reports First Quarter 2017 Financial Results

Tel Aviv, Israel, May 25, 2017 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2017.

·

Reported filing of regulatory submissions to commence a Phase 1b trial for BL-8040 in combination with Genentech’s atezolizumab in acute myeloid leukemia (AML), which will be led by BioLineRx. This study is expected to commence in H2 2017.

 

Philip A. Serlin, Chief Executive Officer of BioLineRx, remarked, “Our 2017 activities have fueled significant excitement at BioLineRx, as we reinforced our position in the high value field of immuno-oncology following our acquisition of a second novel drug compound, AGI-134, and strengthened our balance sheet to fund our main development objectives with support from key fundamental investors.  We ended the first quarter with pro forma cash of $57 million, including net proceeds of $26 million from our recent public offering, sufficient to fund – and accelerate - our clinical programs, including both BL-8040 and AGI-134, through late 2019.”

“With important catalysts in the next 12-18 months, our team is driven and focused on advancing our asset pipeline.  We look forward to providing updates as we execute on our plans,” Mr. Serlin concluded.

Financial Results for the First Quarter Ended March 31, 2017

Research and development expenses for the three months ended March 31, 2017 were $3.6 million, an increase of $1.1 million, or 41%, compared to $2.5 million for the three months ended March 31, 2016. The increase resulted primarily from an increase in spending on BL-8040 and an increase in spending on new projects.

Sales and marketing expenses for the three months ended March 31, 2017 were $0.7 million, an increase of $0.4 million, or 175%, compared to $0.3 million for the three months ended March 31, 2016. The increase resulted primarily from market research activities and one-time professional fees related to business development activities.

General and administrative expenses for the three months ended March 31, 2017 were $1.0 million, similar to the comparable period in 2016.

The company’s operating loss for the three months ended March 31, 2017 amounted to $5.3 million, compared with an operating loss of $3.8 million for the corresponding 2016 period.

Non-operating income (expenses) for the three months ended March 31, 2017 and 2016 were not material, and primarily related to fair-value adjustments of warrant liabilities.

Net financial income amounted to $0.5 million for the three months ended March 31, 2017, compared to net financial income of $0.1 million for the corresponding 2016 period. The increase in net financial income related primarily to gains recorded on foreign currency hedging transactions.

The Company’s net loss for the three months ended March 31, 2017 amounted to $4.9 million, compared with a net loss of $3.5 million for the corresponding 2016 period.

The Company held $30.4 million in cash, cash equivalents and short-term bank deposits as of March 31, 2017. In April 2017, the Company completed an underwritten public offering of its American Depositary Shares for net proceeds of $26.2 million.

Net cash used in operating activities for the three months ended March 31, 2017 was $3.8 million, compared with net cash used in operating activities of $4.2 million for the three months ended March 31, 2016. The $0.4 million decrease in net cash used in operating activities was primarily the result of an increase in trade payables and accruals.

Net cash provided by investing activities for the three months ended March 31, 2017 was $1.4 million, compared to net cash provided by investing activities of $1.7 million for the three months ended March 31, 2016. The changes in cash flows from investing activities relate primarily to investments in, and maturities of, short-term bank deposits, as well as the investment in Agalimmune.

Net cash provided by financing activities for the three months ended March 31, 2017 was $2.1 million, compared to net cash provided by financing activities of $1.6 million for the three months ended March 31, 2016. The increase in cash flows from financing activities primarily reflects funding under the share purchase agreement with LPC.

Conference Call and Webcast Information

BioLineRx will hold a conference call today, March 25, 2017, at 10:00 a.m. EDT. To access the conference call, please dial 1-888-668-9141 from the U.S. or +972-3-918-0609 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx’s website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

A replay of the conference call will be available approximately two hours after completion of the live conference call at the Investor Relations page of BioLineRx’s website. A dial-in replay of the call will be available until May 28, 2017; please dial 1-877-456-0009 from the U.S. or +972-3-925-5946 internationally.

 

(Tables follow)

For additional information on BioLineRx, please visit the Company’s website at www.biolinerx.com, where you can review the Company’s SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

BioLineRx Ltd.

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

		December 31,				March 31,
		2016				2017
		in USD thousands
Assets
CURRENT ASSETS
Cash and cash equivalents			2,469				2,201
Short-term bank deposits			33,154				28,167
Prepaid expenses			255				700
Other receivables			223				580
Total current assets			36,101				31,648
NON-CURRENT ASSETS
Long-term prepaid expenses			52				55
Property and equipment, net			2,605				2,540
Intangible assets, net			181				6,875
Total non-current assets			2,838				9,470
Total assets			38,939				41,118
Liabilities and equity
CURRENT LIABILITIES
Current maturities of long-term bank loan			93				93
Accounts payable and accruals:
Trade			2,590				3,450
Other			978				1,631
Total current liabilities			3,661				5,174
NON-CURRENT LIABILITIES
Long-term bank loan, net of current maturities			250				227
Warrants			1				1
Total non-current liabilities			251				228
COMMITMENTS AND CONTINGENT LIABILITIES
Total liabilities			3,912				5,402
EQUITY
Ordinary shares			1,513				1,642
Share premium			199,567				205,892
Capital reserve			10,569				9,659
Other comprehensive loss			(1,416	)			(1,416	)
Accumulated deficit			(175,206	)			(180,061	)
Total equity			35,027				35,716
Total liabilities and equity			38,939				41,118

 

BioLineRx Ltd.

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

		Three months ended March 31,
		2016				2017
		in USD thousands
RESEARCH AND DEVELOPMENT EXPENSES			(2,539	)			(3,590	)
SALES AND MARKETING EXPENSES			(248	)			(681	)
GENERAL AND ADMINISTRATIVE EXPENSES			(989	)			(1,030	)
OPERATING LOSS			(3,776	)			(5,301	)
NON-OPERATING INCOME (EXPENSES)			148				(5	)
FINANCIAL INCOME			143				457
FINANCIAL EXPENSES			(4	)			(6	)
NET LOSS AND COMPREHENSIVE LOSS			(3,489	)			(4,855	)
		in USD
LOSS PER ORDINARY SHARE - BASIC AND DILUTED			(0.06	)			(0.08	)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE			54,870,561				58,620,094

BioLineRx Ltd.

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

		Ordinary shares				Share premium				Capital Reserve				Other comprehensive loss				Accumulated deficit				Total
		in USD thousands
BALANCE AT JANUARY 1, 2016			1,455				196,201				10,735				(1,416	)			(159,365	)			47,610
CHANGES FOR THREE MONTHS ENDED MARCH 31, 2016:
Issuance of share capital, net			4				1,591				-				-				-				1,595
Share-based compensation			-				-				286				-				-				286
Comprehensive loss for the period			-				-				-				-				(3,489	)			(3,489	)
BALANCE AT MARCH 31, 2016			1,459				197,792				11,021				(1,416	)			(162,854	)			46,002
		Ordinary shares				Share premium				Capital Reserve				Other comprehensive loss				Accumulated deficit				Total
		in USD thousands
BALANCE AT JANUARY 1, 2017			1,513				199,567				10,569				(1,416	)			(175,206	)			35,027
CHANGES FOR THREE MONTHS ENDED MARCH 31, 2017:
Issuance of share capital, net			128				4,944				-				-				-				5,072
Employee stock options exercised			1				296				(297	)			-				-				-
Employee stock options forfeited and expired			-				1,085				(1,085	)			-				-				-
Share-based compensation			-				-				472				-				-				472
Comprehensive loss for the period			-				-				-				-				(4,855	)			(4,855	)
BALANCE AT MARCH 31, 2017			1,642				205,892				9,659				(1,416	)			(180,061	)			35,716

BioLineRx Ltd.

 

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

		Three months ended March 31,
		2016				2017
		in USD thousands
CASH FLOWS - OPERATING ACTIVITIES
Net loss for the period			(3,489	)			(4,855	)
Adjustments required to reflect net cash used in operating activities (see appendix below)			(695	)			1,062
Net cash used in operating activities			(4,184	)			(3,793	)
CASH FLOWS - INVESTING ACTIVITIES
Investments in short-term deposits			(10,300	)			(7,013	)
Maturities of short-term deposits			12,102				12,143
Purchase of property and equipment			(137	)			(45	)
Purchase of intangible assets			(11	)			(3,718	)
Net cash provided by investing activities			1,654				1,367
CASH FLOWS - FINANCING ACTIVITIES
Issuance of share capital and warrants, net of issuance costs			1,595				2,087
Repayments of bank loan			(23	)			(23	)
Net cash provided by financing activities			1,572				2,064
DECREASE IN CASH AND CASH EQUIVALENTS			(958	)			(362	)
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD			5,544				2,469
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS			(2	)			94
CASH AND CASH EQUIVALENTS - END OF PERIOD			4,584				2,201

BioLineRx Ltd.

 

APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

 

		Three months ended March 31,
		2016				2017
		in USD thousands
Adjustments required to reflect net cash used in operating activities:
Income and expenses not involving cash flows:
Depreciation and amortization			122				119
Long-term prepaid expenses			2				(3	)
Exchange differences on cash and cash equivalents			2				(94	)
Gain on adjustment of warrants to fair value			(148	)			-
Share-based compensation			286				472
Interest and exchange differences on short-term deposits			(106	)			(143	)
Interest and linkage differences on bank loan			(1	)			-
			157				351
Changes in operating asset and liability items:
Increase in prepaid expenses and other receivables			(342	)			(802	)
Increase (Decrease) in accounts payable and accruals			(510	)			1,513
			(852	)			711
			(695	)			1,062
Supplementary information on interest received in cash			103				137
Supplementary non-cash investment (see Note 4b)							2,985

 

---

 

---

		Page
Condensed consolidated interim statements of financial position		1
Condensed consolidated interim statements of comprehensive loss		2
Condensed consolidated interim statements of changes in equity		3
Condensed consolidated interim cash flow statements		4-5
Notes to the condensed consolidated interim financial statements		6-8

		December 31,				March 31,
		2016				2017
		in USD thousands
Assets
CURRENT ASSETS
Cash and cash equivalents			2,469				2,201
Short-term bank deposits			33,154				28,167
Prepaid expenses			255				700
Other receivables			223				580
Total current assets			36,101				31,648
NON-CURRENT ASSETS
Long-term prepaid expenses			52				55
Property and equipment, net			2,605				2,540
Intangible assets, net			181				6,875
Total non-current assets			2,838				9,470
Total assets			38,939				41,118
Liabilities and equity
CURRENT LIABILITIES
Current maturities of long-term bank loan			93				93
Accounts payable and accruals:
Trade			2,590				3,450
Other			978				1,631
Total current liabilities			3,661				5,174
NON-CURRENT LIABILITIES
Long-term bank loan, net of current maturities			250				227
Warrants			1				1
Total non-current liabilities			251				228
COMMITMENTS AND CONTINGENT LIABILITIES
Total liabilities			3,912				5,402
EQUITY
Ordinary shares			1,513				1,642
Share premium			199,567				205,892
Capital reserve			10,569				9,659
Other comprehensive loss			(1,416	)			(1,416	)
Accumulated deficit			(175,206	)			(180,061	)
Total equity			35,027				35,716
Total liabilities and equity			38,939				41,118

		Three months ended March 31,
		2016				2017
		in USD thousands
RESEARCH AND DEVELOPMENT EXPENSES			(2,539	)			(3,590	)
SALES AND MARKETING EXPENSES			(248	)			(681	)
GENERAL AND ADMINISTRATIVE EXPENSES			(989	)			(1,030	)
OPERATING LOSS			(3,776	)			(5,301	)
NON-OPERATING INCOME (EXPENSES)			148				(5	)
FINANCIAL INCOME			143				457
FINANCIAL EXPENSES			(4	)			(6	)
NET LOSS AND COMPREHENSIVE LOSS			(3,489	)			(4,855	)
		in USD
LOSS PER ORDINARY SHARE - BASIC AND DILUTED			(0.06	)			(0.08	)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE			54,870,561				58,620,094

		Ordinary shares				Share premium				Capital Reserve				Other comprehensive loss				Accumulated deficit				Total
		in USD thousands
BALANCE AT JANUARY 1, 2016			1,455				196,201				10,735				(1,416	)			(159,365	)			47,610
CHANGES FOR THREE MONTHS ENDED MARCH 31, 2016:
Issuance of share capital, net			4				1,591				-				-				-				1,595
Share-based compensation			-				-				286				-				-				286
Comprehensive loss for the period			-				-				-				-				(3,489	)			(3,489	)
BALANCE AT MARCH 31, 2016			1,459				197,792				11,021				(1,416	)			(162,854	)			46,002
		Ordinary shares				Share premium				Capital Reserve				Other comprehensive loss				Accumulated deficit				Total
		in USD thousands
BALANCE AT JANUARY 1, 2017			1,513				199,567				10,569				(1,416	)			(175,206	)			35,027
CHANGES FOR THREE MONTHS ENDED MARCH 31, 2017:
Issuance of share capital, net			128				4,944				-				-				-				5,072
Employee stock options exercised			1				296				(297	)			-				-				-
Employee stock options forfeited and expired			-				1,085				(1,085	)			-				-				-
Share-based compensation			-				-				472				-				-				472
Comprehensive loss for the period			-				-				-				-				(4,855	)			(4,855	)
BALANCE AT MARCH 31, 2017			1,642				205,892				9,659				(1,416	)			(180,061	)			35,716

		Three months ended March 31,
		2016				2017
		in USD thousands
CASH FLOWS - OPERATING ACTIVITIES
Net loss for the period			(3,489	)			(4,855	)
Adjustments required to reflect net cash used in operating activities (see appendix below)			(695	)			1,062
Net cash used in operating activities			(4,184	)			(3,793	)
CASH FLOWS - INVESTING ACTIVITIES
Investments in short-term deposits			(10,300	)			(7,013	)
Maturities of short-term deposits			12,102				12,143
Purchase of property and equipment			(137	)			(45	)
Purchase of intangible assets			(11	)			(3,718	)
Net cash provided by investing activities			1,654				1,367
CASH FLOWS - FINANCING ACTIVITIES
Issuance of share capital and warrants, net of issuance costs			1,595				2,087
Repayments of bank loan			(23	)			(23	)
Net cash provided by financing activities			1,572				2,064
DECREASE IN CASH AND CASH EQUIVALENTS			(958	)			(362	)
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD			5,544				2,469
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS			(2	)			94
CASH AND CASH EQUIVALENTS - END OF PERIOD			4,584				2,201

		Three months ended March 31,
		2016				2017
		in USD thousands
Adjustments required to reflect net cash used in operating activities:
Income and expenses not involving cash flows:
Depreciation and amortization			122				119
Long-term prepaid expenses			2				(3	)
Exchange differences on cash and cash equivalents			2				(94	)
Gain on adjustment of warrants to fair value			(148	)			-
Share-based compensation			286				472
Interest and exchange differences on short-term deposits			(106	)			(143	)
Interest and linkage differences on bank loan			(1	)			-
			157				351
Changes in operating asset and liability items:
Increase in prepaid expenses and other receivables			(342	)			(802	)
Increase (Decrease) in accounts payable and accruals			(510	)			1,513
			(852	)			711
			(695	)			1,062
Supplementary information on interest received in cash			103				137
Supplementary non-cash investment (see Note 4b)							2,985

		Number of ordinary shares
		December 31,				March 31,
		2016				2017
Authorized share capital			150,000,000				150,000,000
Issued and paid-up share capital			57,033,355				61,782,434
		In USD and NIS
		December 31,				March 31,
			2016				2017
Authorized share capital (in NIS)			15,000,000				15,000,000
Issued and paid-up share capital (in NIS)			5,703,336				6,178,243
Issued and paid-up share capital (in USD)			1,513,294				1,642,162

 

---

 

OPERATING AND FINANCIAL REVIEW

 

You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as in our Annual Report on Form 20-F filed on March 23, 2017 (the “Annual Report”).

 

Forward Looking Statements

 

The following discussion contains “forward-looking statements,” including statements regarding expectations, beliefs, intentions or strategies for the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions, and are subject to risks and uncertainties. You should not put undue reliance on any forward-looking statements. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those listed below as well as those discussed in the Annual Report (particularly those in “Item 3. Key Information – Risk Factors”). Unless we are required to do so under U.S. federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements.

 

Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

 

·

the initiation, timing, progress and results of our preclinical studies, clinical trials and other therapeutic candidate development efforts;

 

·

our ability to advance our therapeutic candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;

 

·

our receipt of regulatory approvals for our therapeutic candidates, and the timing of other regulatory filings and approvals;

 

·

the clinical development, commercialization and market acceptance of our therapeutic candidates;

 

·

our ability to establish and maintain corporate collaborations;

 

·

our ability to integrate new therapeutic candidates and new personnel

 

·

the interpretation of the properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic candidates in preclinical studies or clinical trials;

 

·

the implementation of our business model and strategic plans for our business and therapeutic candidates;

 

·

the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others;

 

·

estimates of our expenses, future revenues, capital requirements and our needs for additional financing;

 

·

competitive companies, technologies and our industry; and

 

·

the impact of the political and security situation in Israel on our business.

 

 

Overview

 

General

 

We are a clinical-stage biopharmaceutical development company focused on oncology and immunology. Our current development and commercialization pipeline consists of a clinical-stage therapeutic candidate, BL-8040; a near-clinical therapeutic candidate, AGI-134; and one commercialized product, BL-5010. In addition, we have five other therapeutic candidates in clinical and pre-clinical development. We generate our pipeline by systematically identifying, rigorously validating and in-licensing therapeutic candidates that we believe exhibit a relatively high probability of therapeutic and commercial success. Our strategy includes commercializing our therapeutic candidates through out-licensing arrangements with biotechnology and pharmaceutical companies and evaluating, on a case by case basis, the commercialization of our therapeutic candidates independently. Although our focus is principally on the therapeutic areas of oncology and immunology, we may also in-license therapeutic compounds outside of these areas in connection with our strategic collaboration with Novartis, as well as to a limited extent for our independent pipeline as the opportunities arise.

 

Main Therapeutic Candidates

 

The following is a description of our main programs:

 

•

BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which we are developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation.

 

Solid tumors

 

Ø

In January 2016, we entered into a collaboration with MSD, known as Merck in the U.S. and Canada, in the field of cancer immunotherapy. Based on this collaboration, in September 2016 we initiated a Phase 2a study, known as the COMBAT study, focusing on evaluating the safety and efficacy of BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in up to 30 patients with metastatic pancreatic adenocarcinoma. The study is an open-label, multicenter, single-arm trial designed to evaluate the clinical response, safety and tolerability of the combination of these therapies as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity. Partial results are expected in the second half of 2017, top-line results in the second half of 2018.

 

Ø

In August 2016, by way of an agreement with MD Anderson Cancer Center, we entered into an additional collaboration for the investigation of BL-8040 in combination with KEYTRUDA in pancreatic cancer. We are supplying BL-8040 for a Phase 2a study which commenced in January 2017.

 

Ø

In September 2016, we entered into a collaboration with Genentech, Inc., a member of the Roche Group, to support several Phase 1b studies investigating BL-8040 in combination with atezolizumab, Genentech’s anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies, which are all expected to commence in 2017, will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in various solid tumors and hematologic malignancies.

 

AML

 

Ø

During 2016, we completed and reported on a Phase 2a proof-of-concept trial for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) which was conducted at six world-leading cancer research centers in the U.S. and at five premier sites in Israel. At the annual meetings of SOHO and ASH in September and December 2016, respectively, we presented detailed, positive results of the study.

 

Ø

BL-8040 is also being investigated as a consolidation treatment together with cytarabine (the current standard of care) for AML patients who have responded to standard induction treatment and are in complete remission. In this regard, we are currently running a significant Phase 2b trial in Germany, in collaboration with the German Study Alliance Leukemia Group. The Phase 2b trial is a double-blind, placebo-controlled, randomized, multi-center study aimed at assessing the efficacy of BL-8040 in addition to standard consolidation therapy in AML patients. Up to 194 patients will be enrolled in the trial. The primary endpoint of the study is to compare the relapse-free survival (RFS) time in AML subjects in their first remission during a minimum follow-up time of 18 months after randomization. We are considering performing an interim analysis on this study in 2018, with top-line results expected in 2019.

 

Stem-cell mobilization

 

Ø

In March 2015, we reported successful top-line safety and efficacy results from a Phase 1 safety and efficacy trial for the use of BL-8040 as a novel stem-cell mobilization treatment for allogeneic bone marrow transplantation at Hadassah Medical Center in Jerusalem.

 

Ø

In March 2016, we announced the initiation of a Phase 2 trial for BL-8040 for allogeneic stem-cell transplantation, conducted in collaboration with the Washington University School of Medicine, Division of Oncology and Hematology. Initial results of this study announced in March 2017 show that a single injection of BL-8040 mobilized sufficient amounts of cells required for transplantation at a level of efficacy similar to that achieved by using 4-6 injections of G-CSF, the current standard of care. Topline results in this study are expected by the end of 2017.

 

Ø

In April 2017, we met with the FDA to discuss the clinical development pathway towards registration of BL-8040 as a stem-cell mobilization treatment for autologous bone-marrow transplantation. Our proposed clinical development pathway was based on prior understandings with the FDA achieved based on results from a Phase 1 trial for autologous stem-cell mobilization and transplantation in multiple myeloma patients completed in 2010. Following our recent successful meeting, we announced our plans to commence a phase 3 registration study in autologous stem cell mobilization in the second half of 2017.

 

Other matters

 

Ø

In addition to the above, we are currently conducting, or planning to conduct, a number of investigator-initiated, open-label studies in a variety of indications, to support the interest of the scientific and medical communities in exploring additional uses for BL-8040. These studies serve to further elucidate the mechanism of action for BL-8040.

 

Ø

In September 2013, the FDA granted an Orphan Drug Designation to BL-8040 as a therapeutic for the treatment of AML; and in January 2014, the FDA granted an Orphan Drug Designation to BL-8040 as a treatment for stem cell mobilization. In January 2015, the FDA modified this Orphan Drug Designation for BL-8040 for use either as a single agent or in combination with G-CSF.

 

•

AGI-134, a near-clinical therapeutic candidate in-licensed by Agalimmune Ltd., or Agalimmune, is a synthetic alpha-Gal glycolipid immunotherapy in development for solid tumors. AGI-134 harnesses the body’s pre-existing, highly abundant, anti-alpha-Gal antibodies to induce a systemic, specific anti-tumor response to the patient’s own tumor neo-antigens. This response not only kills the tumor cells at the site of injection, but also brings about a durable, follow-on, anti-metastatic immune response. AGI-134 has completed numerous proof-of-concept studies, demonstrating robust protection against the development of secondary tumors in a model of melanoma with a single dose only. Synergy has also been demonstrated in the same model when combined with a PD-1 immune checkpoint inhibitor, offering the potential to broaden the utility of such immunotherapies and improve the rate and duration of responses in multiple cancer types. We expect to commence a first-in-man study using AGI-134 in patients with solid tumors in the first half of 2018.

 

•

BL-5010 is a customized, proprietary pen-like applicator containing a novel, acidic, aqueous solution for the non-surgical removal of skin lesions. In December 2010, we announced positive results from a Phase 1/2 clinical trial of BL-5010. In June 2011, we received European confirmation from BSI of the regulatory pathway classification of BL-5010 as a Class IIa medical device. In December 2014, we entered into an exclusive out-licensing arrangement with Omega Pharma, now part of Perrigo Company plc, for the rights to BL-5010 for over-the-counter, or OTC, indications in the territory of Europe, Australia and additional selected countries. During 2015, Omega Pharma conducted a 30-patient, open-label clinical study in Turkey to evaluate the advantages of BL-5010 in one of the intended OTC indications. Study results indicate that BL-5010 is safe and efficacious. In March 2016, Omega Pharma received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of warts. The commercial launch of this first OTC indication (warts/verrucas) commenced in Europe in the second quarter of 2016 and sales are expected to slowly ramp up over the next 2-3 years.

 

Principal Partnering and Collaboration Agreements

 

In December 2014, we entered into a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates. Under the agreement, we intend, in collaboration with Novartis, to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept for potential future licensing by Novartis. During 2016, we in-licensed three pre-clinical projects – BL-1210, BL-1220 and BL-1230 – in the framework of this collaboration. Through the date of this report, Novartis has flagged several late-stage, pre-clinical projects, some of which we may bring into our pipeline during 2017.

 

In December 2014, we entered into an exclusive out-licensing arrangement with Omega Pharma for the rights to BL-5010 for over-the-counter or OTC indications in the territory of Europe, Australia and additional selected countries. We retain all OTC rights to BL-5010 in the United States and the rest of the world, as well as all non-OTC rights on a global basis. Under our out-licensing arrangement with Omega Pharma, Omega Pharma is obligated to use commercially reasonable best efforts to obtain regulatory approval in the licensed territory for at least two OTC indications and to commercialize BL-5010 for those two OTC indications. In addition, Omega Pharma will sponsor and manufacture BL-5010 in the relevant regions. Omega Pharma will pay us an agreed amount for each unit sold, and we will be entitled to certain commercial milestone payments. We will have full access to all clinical and research and development data, as well as manufacturing data, generated during the performance of the development plan and may use these data in order to develop or license the product in other territories and fields of use where we retain the rights.

 

For information on our collaborations with Merck, Genentech and MD Anderson Cancer Center, see “― Main Therapeutic Candidates” above.

 

Other Partnering and Collaboration Agreements

 

In August 2016, we announced the establishment of a joint venture with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and pre-clinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets. Under the terms of the joint venture agreement, each partner will provide seed capital of one million dollars to the venture. We will screen and identify promising early-stage drug candidates originating primarily in Israel with emphasis on therapeutic indications that are of special interest for the Chinese population. These therapeutic candidates will then be in-licensed by iPharma for further development and commercialization in China and possibly in other countries as well. The project screening process has begun and the in-licensing of two candidates is being negotiated.

 

In 2009, we entered into an exclusive, worldwide, royalty-bearing licensing arrangement with Bellerophon. Under the agreement, we granted Bellerophon an exclusive, worldwide license to develop, manufacture and commercialize BL-1040 for use in the prevention, mitigation and treatment of injuries to the myocardial tissue of the heart. Under the arrangement, Bellerophon is obligated to use commercially reasonable efforts to complete clinical development of, and to commercialize, BL-1040 or products related thereto.

 

In January 2014, we signed a collaboration agreement with JHL Biotech, or JHL, a biopharmaceutical company that develops, manufactures, and commercializes biologic medicines, pursuant to which we will collaborate with JHL in the development and commercialization of BL-9020, a novel monoclonal antibody in the preclinical development stage for the treatment of Type 1 diabetes. JHL Biotech is responsible for all process development and manufacturing of BL-9020 during its pre-clinical and clinical development stages, and we are responsible for all pre-clinical development of BL-9020.

 

Funding

 

We have funded our operations primarily through the sale of equity securities (both in public and private offerings), funding received from a government body which previously was called the Office of the Chief Scientist of the Israeli Ministry of the Economy (OCS) (and which in 2016 was replaced by the newly established Israel Innovation Authority), payments received under out-licensing arrangements, and interest earned on investments. We expect to continue to fund our operations over the next several years through our existing cash resources, potential future milestone and royalty payments that we may receive from our existing out-licensing agreements, potential future upfront or milestone payments that we may receive from out-licensing transactions for our other therapeutic candidates, interest earned on our investments and additional capital to be raised through public or private equity offerings or debt financings. As of March 31, 2017, we held $30.4 million of cash, cash equivalents and short-term bank deposits. In April 2017, we raised an additional $26.2 million in net proceeds from a public offering of our ADSs.

 

Recent Company Developments

 

Acquisition of Agalimmune

 

In March 2017, we acquired substantially all the outstanding shares of Agalimmune, a privately-held company incorporated in the United Kingdom. Acquisition consideration consisted of an upfront payment of $6 million, of which $3 million was in cash and the remainder in the Company’s ADSs. Additional future payments may be made based on development and commercial milestones. The acquisition expands our pipeline to include Agalimmune’s primary asset, AGI-134, a near-clinical, immuno-oncology agent for various cancer indications. We expect to commence a first-in-man study using AGI-134 in patients with solid tumors in the first half of 2018. The transaction was accounted for as an asset acquisition.

 

Changes in Company Management

 

 

Pre-Clinical and Clinical Development

 

In January 2017, we announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA^® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The study, for which we are supplying BL-8040, is being conducted as an investigator-sponsored study, as part of a strategic clinical research collaboration between Merck and MD Anderson Cancer Center aimed at evaluating KEYTRUDA in combination with various treatments and novel drugs, including BL-8040. The open-label, single center, single-arm Phase 2a study is focusing on the mechanism of action by which KEYTRUDA and BL-8040 might synergize. In addition to assessing clinical response, the study includes multiple assessments to evaluate the biological anti-tumor effects induced by the combination.

 

In March 2017, we reported partial results data from our open-label Phase 2 trial for BL-8040 as a novel monotherapy approach for the mobilization and collection of blood forming stem and progenitor cells from the peripheral blood. The study consists of donor and patient pairs for allogeneic hematopoietic cell transplantation. The first part of the study, which is nearing completion, is intended to enroll an initial cohort of 10 donor and recipient pairs, consisting of patients with advanced hematological malignancies and their HLA-matched sibling donors. Interim results show that a single injection of BL-8040 mobilized sufficient amounts of cells required for transplantation at a level of efficacy similar to that achieved by using 4-6 injections of G-CSF, the current standard of care. Furthermore, all recipients transplanted so far have experienced a successful neutrophil engraftment. The recipients will be followed for one year to assess acute and chronic GVHD events. As for the donors, BL-8040 treatment was safe and well tolerated.

 

In April 2017, AGI-134 was featured at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC held on April 1-5, 2017. An abstract titled “The novel α-Gal-based immunotherapy AGI-134 invokes CD8+ T cell-mediated immunity by driving tumor cell destruction, phagocytosis and tumor-associated antigen cross-presentation via multiple antibody-mediated effector functions” was presented in a poster at the T-Cell Immunity to Cancer: New Progress session.

 

In April 2017, we met with the FDA to discuss the clinical development pathway towards registration of BL-8040 as a stem-cell mobilization treatment for autologous bone-marrow transplantation. Following this successful meeting, we announced our plans to commence a phase 3 registration study in autologous stem cell mobilization in the second half of 2017. The study will investigate BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of stem cells from the bone marrow to the peripheral blood, followed by collection and subsequent autologous transplantation in patients with multiple myeloma.

 

Capital Resources

 

In April 2017, we closed an underwritten public offering of approximately 33.8 million of our ADSs for gross proceeds of $28.75 million and net proceeds of $26.2 million, after deducting fees and expenses. The public offering price was $0.85 per ADS.

 

Addition and Termination of Therapeutic Candidates

 

As part of our business strategy, we continue to actively source, rigorously evaluate and in-license selected therapeutic candidates. In line with our business strategy, during the period beginning January 1, 2017 through the date of this announcement, we added AGI-134 as described above and, in light of scientific, regulatory and commercial considerations, terminated BL-7010. BL-7010 was intended for the treatment of celiac disease and gluten sensitivity.

 

Revenues

 

Our revenues to date have been generated primarily from milestone payments under current and previously existing out-licensing agreements.

 

We expect our revenues for the next several years to be derived primarily from future payments under our current out-licensing agreement with Omega Pharma, our collaboration agreement with Novartis and other potential collaboration arrangements, including future royalties on product sales.

 

Research and Development

 

Our research and development expenses consist primarily of salaries and related personnel expenses, fees paid to external service providers, up-front and milestone payments under our license agreements, patent-related legal fees, costs of preclinical studies and clinical trials, drug and laboratory supplies and costs for facilities and equipment. We primarily use external service providers to manufacture our product candidates for clinical trials and for the majority of our preclinical and clinical development work. We charge all research and development expenses to operations as they are incurred. We expect our research and development expense to remain our primary expense in the near future as we continue to develop our therapeutic candidates.

 

The following table identifies our current major research and development projects:

Project	Status	Expected Near Term Milestones
	1.  Phase 2a study for relapsed or refractory AML completed	1.   Follow-up for overall survival rate is ongoing
	2.  Phase 2b consolidation treatment for AML ongoing	2.   Completion of enrollment and possible interim results expected in H2 2018; top-line results expected in H2 2019
	3.  Phase 2 study in stem cell mobilization ongoing	3.   Top-line results expected in Q4 2017.
	4.  Phase 2a study in pancreatic cancer, in collaboration with Merck, ongoing	4.   Partial results expected in H2 2017; top-line results expected in H2 2018
BL-8040	5.  Phase 2a study in pancreatic cancer, in collaboration with MD Anderson Cancer Center, ongoing	5.   Top-line results expected in H2 2018
	6.  Phase 1b study in AML, in collaboration with Genentech, regulatory submission made	6.   Commencement of study expected in H2 2017; top-line results expected in 2019
	7.  Phase 1b studies in various solid tumors, in collaboration with Genentech, in final planning stages	7.   Commencement of studies expected in H2 2017; top-line results expected in 2019
	8.  Phase 3 registration study in autologous stem cell mobilization in final planning stages	8.   Commencement of study expected in H2 2017
AGI-134	Near-clinical development studies	Regulatory submission for first-in-man study expected in H2 2017; commencement of study expected in H1 2018
BL-5010	Out-licensed to Omega Pharma; CE mark approval obtained; commercial launch of first OTC indication in Europe commenced	Gradual full roll-out of commercial launch over next two-three years; pursuit of potential out-licensing partner(s) for OTC and non-OTC rights still held by us

In addition to the projects set forth above, we have five additional projects in clinical and pre-clinical stages of development (BL-9020, BL-1210, BL-1220, BL-1230 and BL-1040) that are significantly less material to the Company’s ongoing research and development expenditures.

 

Set forth below is a summary of the costs allocated to our main projects on an individual basis, as well as the costs allocated to our less significant projects on an aggregate basis, for the years ended December 31, 2014, 2015 and 2016; for the three months ended March 31, 2017; and on an aggregate basis since project inception.

 

		Year Ended December 31,												Three Months Ended March 31,				Total Costs Since Project
		2014				2015				2016				2017				Inception
		(in thousands of U.S. dollars)
BL-8040			4,698				7,045				8,281				2,565				27,222
BL-5010			1,282				400				75				-				4,144
Other projects			5,293				3,573				2,647				930				115,061
Total gross direct project costs			11,273				11,018				11,003				3,495				146,427

 

From our inception through March 31, 2017, we have incurred research and development expense of approximately $180.6 million. We expect that a large percentage of our research and development expense in the future will be incurred in support of our current and future preclinical and clinical development projects. Due to the inherently unpredictable nature of preclinical and clinical development processes and given the early stage of our preclinical product development projects, we are unable to estimate with any certainty the costs we will incur in the continued development of the therapeutic candidates in our pipeline for potential commercialization. Clinical development timelines, the probability of success and development costs can differ materially from expectations. We expect to continue to test our product candidates in preclinical studies for toxicology, safety and efficacy, and to conduct additional clinical trials for each product candidate. If we are not able to enter into an out-licensing arrangement with respect to any therapeutic candidate prior to the commencement of later stage clinical trials, we may fund the trials for the therapeutic candidate ourselves.

 

While we are currently focused on advancing each of our product development projects, our future research and development expenses will depend on the clinical success of each therapeutic candidate, as well as ongoing assessments of each therapeutic candidate’s commercial potential. In addition, we cannot forecast with any degree of certainty which therapeutic candidates may be subject to future out-licensing arrangements, when such out-licensing arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

 

As we obtain results from clinical trials, we may elect to discontinue or delay clinical trials for certain therapeutic candidates or projects in order to focus our resources on more promising therapeutic candidates or projects. Completion of clinical trials by us or our licensees may take several years or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a therapeutic candidate.

 

The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:

 

·

the number of sites included in the clinical trials;

 

·

the length of time required to enroll suitable patients;

 

·

the number of patients that participate in the clinical trials;

 

·

the duration of patient follow-up;

 

·

whether the patients require hospitalization or can be treated on an out-patient basis;

 

·

the development stage of the therapeutic candidate; and

 

·

the efficacy and safety profile of the therapeutic candidate.

 

We expect our research and development expenses to remain our most significant cost as we continue the advancement of our clinical trials and preclinical product development projects and place significant emphasis on in-licensing new product candidates. The lengthy process of completing clinical trials and seeking regulatory approval for our product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. Due to the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects.

 

Sales and Marketing Expenses

 

Sales and marketing expenses consist primarily of compensation for employees in business development and marketing functions. Other significant sales and marketing costs include costs for marketing and communication materials, professional fees for outside market research and consulting, legal services related to partnering transactions and travel costs.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of compensation for employees in executive and operational functions, including accounting, finance, legal, investor relations, information technology and human resources. Other significant general and administration costs include facilities costs, professional fees for outside accounting and legal services, travel costs, insurance premiums and depreciation.

 

Non-Operating Expense and Income

 

Non-operating expense and income includes fair-value adjustments of liabilities on account of the warrants issued in the private and direct placements which we conducted in February 2012 and 2013. These fair-value adjustments are highly influenced by our share price at each period end (revaluation date). Non-operating expense and income also includes the pro-rata share of issuance expenses from the placements related to the warrants. In addition, non-operating expense and income includes the initial commitment and finder’s fees, as well as other one-time expenses, associated with the initial set-up of a share purchase agreement with Lincoln Park Capital, or LPC.

 

Financial Expense and Income

 

Financial expense and income consists of interest earned on our cash, cash equivalents and short-term bank deposits; bank fees and other transactional costs. In addition, it may also include gains/losses on foreign exchange hedging transactions, which we carry out from time to time to protect against a portion of our NIS-denominated expenses (primarily compensation) in relation to the dollar.

 

Significant Accounting Policies and Estimates

 

We describe our significant accounting policies more fully in Note 2 to our consolidated financial statements for the year ended December 31, 2016.

 

The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepare in accordance with IFRS. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

Results of Operations – Overview

 

Revenues

 

We did not record any revenues during each of the three-month periods ended March 31, 2017 and 2016.

 

Cost of revenues

 

We did not record any cost of revenues during each of the three-month periods ended March 31, 2017 and 2016.

 

Research and development expenses

 

At December 31, 2013, our drug development pipeline consisted of 10 therapeutic candidates. During 2014, we added a new compound to our pipeline and discontinued the development of two compounds from the pipeline, so that our drug development pipeline as of December 31, 2014 consisted of nine therapeutic candidates. During 2015, we did not add any new compounds to our pipeline and we discontinued the development of one compound from the pipeline, so that our drug development pipeline as of December 31, 2015 consisted of eight therapeutic candidates. During 2016, we added three compounds to our pipeline and discontinued the development of three compounds in our pipeline, so that our drug development pipeline of as of December 31, 2016 consisted of eight therapeutic candidates. Subsequent to December 31, 2016, we terminated one therapeutic candidate in our pipeline, and added one therapeutic candidate to the pipeline, so that our drug development pipeline of the date of this report consists of eight therapeutic candidates.

 

Operating Results Comparison between Periods

 

Revenues and cost of revenues

 

See discussion under “Results of Operations - Overview” above.

 

Research and development expenses

 

		Three months ended March 31,
		2016				2017				Increase (decrease)
		(in thousands of U.S. dollars)
Research and development expenses			2,539				3,590				1,051

Research and development expenses for the three months ended March 31, 2017 were $3.6 million, an increase of $1.1 million, or 41%, compared to $2.5 million for the three months ended March 31, 2016. The increase resulted primarily from an increase in spending on BL-8040 and an increase on spending on new projects.

 

Sales and marketing expenses

 

		Three months ended March 31,
		2016				2017				Increase (decrease)
		(in thousands of U.S. dollars)
Sales and marketing expenses			248				681				433

 

General and administrative expenses

 

		Three months ended March 31,
		2016				2017				Increase (decrease)
		(in thousands of U.S. dollars)
General and administrative expenses			989				1,030				41

 

Non-operating income (expenses), net

 

		Three months ended March 31,
		2016				2017				Increase (decrease)
		(in thousands of U.S. dollars)
Non-operating income (expenses), net			148				(5	)			(153	)

Non-operating income (expenses) for the three months ended March 31, 2017 and 2016 were not material, and primarily relate to fair-value adjustments of warrant liabilities on our balance sheet. These fair-value adjustments are highly influenced by our share price at each period end (revaluation date).

 

Financial income (expenses), net

 

		Three months ended March 31,
		2016				2017				Increase (decrease)
		(in thousands of U.S. dollars)
Financial income			143				457				314
Financial expenses			(4	)			(6	)			(2	)
Net financial income (expenses)			139				451				312

We recognized net financial income of $0.5 million for the three months ended March 31, 2017 compared to net financial income of $0.1 million for the three months ended March 31, 2016. The increase in net financial income relates primarily to gains recorded on foreign currency hedging transactions.

 

Liquidity and Capital Resources

 

Since inception, we have funded our operations primarily through public and private offerings of our equity securities, funding from the OCS, and payments received under our strategic licensing arrangements. At March 31, 2017, we held $30.4 million in cash, cash equivalents and short-term bank deposits. We have invested substantially all our available cash funds in short-term bank deposits. In April 2017, we raised an additional $26.2 million in net proceeds from a public offering of our ADSs.

 

Pursuant to the share purchase agreement signed with LPC in May 2014, we may sell, from time to time, and at our discretion, up to $20 million of our ADSs to LPC during the 36-month term of the purchase agreement. From the effective date of the purchase agreement through the date of this report, we have sold an aggregate of approximately $7.0 million of our ADSs to LPC, leaving an available balance under the facility of approximately $13.0 million. The share purchase agreement with LPC will expire in accordance with its terms on July 1, 2017

 

Net cash used in operating activities was $3.8 million for the three months ended March 31, 2017, compared with net cash used in operating activities of $4.2 million for the three months ended March 31, 2016. The $0.4 million decrease in net cash used in operating activities during the three-month period in 2017, compared to the three-month period in 2016, was primarily the result of an increase in trade payables and accruals.

 

Net cash provided by investing activities for the three months ended March 31, 2017 was $1.4 million, compared to net cash provided by investing activities of $1.7 million for the three months ended March 31, 2016. The changes in cash flows from investing activities relate primarily to investments in, and maturities of, short-term bank deposits, as well as the investment in Agalimmune.

 

Net cash provided by financing activities for the three months ended March 31, 2017 was $2.1 million, compared to net cash provided by financing activities of $1.6 million for the three months ended March 31, 2016. The increase in cash flows from financing activities primarily reflects funding under the share purchase agreement with LPC.

 

Developing drugs, conducting clinical trials and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic objectives. Although we believe our existing cash and other resources will be sufficient to fund our projected cash requirements into 2019, we will require significant additional financing in the future to fund our operations. Our future capital requirements will depend on many factors, including:

 

·

the progress and costs of our preclinical studies, clinical trials and other research and development activities;

 

·

the scope, prioritization and number of our clinical trials and other research and development programs;

 

·

the amount of revenues we receive under our collaboration or licensing arrangements;

 

·

the costs of the development and expansion of our operational infrastructure;

 

·

the costs and timing of obtaining regulatory approval of our therapeutic candidates;

 

·

the ability of our collaborators to achieve development milestones, marketing approval and other events or developments under our collaboration agreements;

 

·

the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;

 

·

the costs and timing of securing manufacturing arrangements for clinical or commercial production;

 

·

the costs of establishing sales and marketing capabilities or contracting with third parties to provide these capabilities for us;

 

·

the costs of acquiring or undertaking development and commercialization efforts for any future product candidates;

 

·

the magnitude of our general and administrative expenses;

 

·

any cost that we may incur under current and future licensing arrangements relating to our therapeutic candidates; and

 

·

payments to the OCS.

 

Until we can generate significant continuing revenues, we expect to satisfy our future cash needs through payments received under our collaborations, debt or equity financings, or by out-licensing other product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, or at all.

 

If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs or our commercialization efforts.

 

Off-Balance Sheet Arrangements

 

Since inception, we have not entered into any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

 

---